| Q38175320 | Androgen receptor signaling in prostate cancer. |
| Q91559729 | Biological insights into multiple birth: genetic findings from UK Biobank |
| Q38829200 | Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo. |
| Q38754074 | Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. |
| Q38743542 | Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome. |
| Q58605544 | Developing Practical Therapeutic Strategies that Target Protein SUMOylation |
| Q35712961 | GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells |
| Q38727020 | Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. |
| Q37120262 | IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9. |
| Q42506716 | Identification of novel NF-κB transcriptional targets in TNFα-treated HeLa and HepG2 cells |
| Q38055760 | Interleukin-6 as a therapy target in oral squamous carcinoma |
| Q48183570 | Mechanical cue-induced YAP instructs Skp2-dependent cell cycle exit and oncogenic signaling. |
| Q35742477 | Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy |
| Q47109527 | Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer |
| Q92861949 | Negative regulators of STAT3 signaling pathway in cancers |
| Q36984471 | PIAS1 Promotes Lymphomagenesis through MYC Upregulation |
| Q35068026 | PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells |
| Q36896806 | PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. |
| Q42493887 | PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer |
| Q28590257 | Protein inhibitor of activated STAT 1 (PIAS1) is identified as the SUMO E3 ligase of CCAAT/enhancer-binding protein β (C/EBPβ) during adipogenesis |
| Q89664232 | Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility |
| Q38724557 | Regulation of ULK1 Expression and Autophagy by STAT1. |
| Q37533348 | SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. |
| Q36243599 | STAT1-deficient mice are resistant to cecal ligation and puncture-induced septic shock |
| Q39108925 | SUMO and the robustness of cancer |
| Q38924091 | SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. |
| Q38515816 | SUMO pathway components as possible cancer biomarkers |
| Q35245641 | SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases |
| Q38132691 | SUMO rules: regulatory concepts and their implication in neurologic functions. |
| Q90631397 | SUMOylation Is Required for ERK5 Nuclear Translocation and ERK5-Mediated Cancer Cell Proliferation |
| Q39019431 | SUMOylation proteins in breast cancer |
| Q26776081 | SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer |
| Q38118140 | Starting and stopping SUMOylation. What regulates the regulator? |
| Q38848340 | Steroid Hormone Receptor Coregulators in Endocrine Cancers |
| Q40332990 | Sumoylation as an Integral Mechanism in Bacterial Infection and Disease Progression |
| Q39194387 | The Role of PIAS SUMO E3-Ligases in Cancer |
| Q91940275 | Writing and erasing MYC ubiquitination and SUMOylation |